Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 3
Submit an article Journal homepage
203
Views
3
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma

Brian T. HillDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
,
Mitchell R. SmithGeorge Washington University, Washington, DC, USA; View further author information
,
Meredeth ShelleyDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
,
Deepa JagadeeshDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
,
Robert M. DeanDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
,
Brad PohlmanDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
,
John W. SweetenhamHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; View further author information
,
Brian J. BolwellDepartment of Hematology & Medical Oncology Cleveland, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; View further author information
&
Stephen D. SmithDepartment of Internal Medicine, Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USACorrespondence[email protected]
View further author information
 show all
Pages 690-694 | Received 08 May 2017, Accepted 23 Jun 2017, Published online: 11 Jul 2017

References

  • Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin’s lymphoma. Int J Cancer. 2006;119:971–979.
  • Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–360.
  • Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
  • Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:667–675.
  • O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684.
  • Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100:657–666.
  • Wang M, Popplewell LL, Collins RH Jr, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165:510–518.
  • Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19:6882–6890.
  • Conconi A, Raderer M, Franceschetti S, et al. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol. 2014;166:69–76.
  • Haritunians T, Mori A, O’Kelly J, et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007;21:333–339.
  • Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374–14379.
  • Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138:783–791.
  • Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
  • Witzig T, Tobinai K, Rigacci L, et al. PILLAR-2: a randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). JCO. 2016;34(suppl):abstr 7506.
  • Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis. Crit Rev Oncol/Hematol. 2013;88:30–41.
  • Xiao Y, Yin J, Wei J, et al. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e87671.
  • Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508–514.
  • Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
  • Ghobrial IM, Redd R, Armand P, et al. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015;29:2338–2346.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.